IDEXX Laboratories reported first-quarter revenue of $900 million, an 8% increase, with EPS of $2.55, a 12% increase. The results were driven by Companion Animal Group diagnostics recurring revenue growth and supported by a $16 million customer contract resolution payment.
IDEXX achieved first quarter revenue growth of 8% reported and 10% organic, driven by CAG Diagnostics recurring revenue growth of 9% reported and 12% organic
Strong organic revenue growth supported by IDEXX execution drivers, including record first quarter global premium instrument placements
Delivered EPS of $2.55, supported by operating margin expansion of 150 basis points as reported and 210 basis points on a comparable basis
Incorporated positive adjustments to full year revenue and EPS guidance ranges, raising low end and maintaining consistent targeted strong performance at high end
The Company is updating its full year revenue growth outlook range to 7.5% - 10% as reported and organically and EPS outlook range of $9.33 - $9.75.
Visualization of income flow from segment revenue to net income